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TGF- isoforms in renal fibrogenesis.
Background. Transforming growth factor-1 (TGF-1) is
generally considered to be the major or predominant isoform
involved in fibrosis, with the roles of TGF-2 and -3 being
less clear. Because anti-TGF-–specific isoform treatment is
in development, it is important to know more precisely about
isoform action. Here we compared the actions of each isoform
on production and degradation of extracellular matrix proteins
by cultured rat mesangial cells, renal fibroblasts, and tubular
epithelial cells. We investigated endogenous production of each
isoform, the effect of adding one isoform on the production
of the other isoforms, and the response to addition of isoform
combinations on matrix protein production. Isoform-specific
antibodies were used to determine the relative contribution of
these isoforms to matrix protein production.
Methods. Each cell type was treated with TGF- (0.01 to
10 ng/mL) alone or in different combinations. Living cell num-
ber was determined by 3-[4,5]dimethylthiazol-2,5-diphenyl-
tetrazolium bromide (MTT) assay. Supernatant fibronectin and
TGF- isoform concentration were measured by enzyme-linked
immunosorbent assay (ELISA). Collagen and proteoglycan
production were measured by [3H]-proline and [35S]-sulfate
incorporation, respectively. Matrix protein and TGF- isoform
gene expression were determined by Northern blot. Release
of 3H from preformed radiolabeled matrix by fibroblasts was
used as a measure of matrix degradation.
Results. Each isoform increased matrix protein synthesis and
reduced matrix degradation by renal cells similarly. Combination
of TGF- isoforms showed additive effects. No antifibrotic effect
was observed with TGF-3. TGF-1 increased -2 and -3 pro-
duction in a small and inconsistent manner. In contrast, TGF-2
and -3 stimulated TGF-1 in all three cell types. Eighty per-
cent of TGF-3’s fibrogenic effect was mediated by TGF-1.
A pan-specific antibody to TGF- most effectively blocked
plasminogen activator inhibitor type 1 (PAI-1) synthesis by
epithelial cells under oxidative stress.
Conclusion. All three TGF- isoforms have fibrogenic ef-
fects on renal cells. TGF-2 and TGF-3 effects may be par-
tially mediated by TGF-1. These data suggest that blockade
of all isoforms together may yield the best therapeutic effect
in reducing renal fibrosis.
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Transforming growth factor-1 (TGF-1) is a key me-
diator of fibrosis. The original observation that TGF-1
overexpression is involved in fibrosis in an acute model
of mesangioproliferative glomerulonephritis has been
confirmed in many fibrotic disorders of the kidney and
other organs [1, 2]. There has been much emphasis on
blockade of TGF- as a therapeutic strategy [3]. How-
ever, TGF-1 overexpression does not dominate all fi-
brogenic processes. TGF-2 has been reported to be dom-
inant in the acute phase of nephropathy in streptozotocin
(STZ)-induced type I diabetes in the rat [4]. Subsequently,
administration of neutralizing antibody to TGF-2 dur-
ing the acute phase of diabetes in the STZ rat significantly
reduced renal fibrosis [5]. TGF-2 is also the predomi-
nant isoform in ocular scarring and again, TGF-2 anti-
body therapy reduces scarring following glaucoma sur-
gery [6–8]. However, in general, compared with TGF-1,
the roles of TGF-2 and TGF-3 in fibrosis are not
precisely known.
While much is known about developmental expression
of TGF- isoforms, differences in the three isoforms in
terms of fibrogenesis is less well studied. The limited publi-
cations in this field generally show similar profibrotic ef-
fects of all three isoforms [9, 10]. However, controversial
results have been reported for TGF-3. Shah et al [11]
found that TGF-3 applied to dermal wounds had anti-
fibrotic effects. Later, Murata et al [12] observed that
the increases in 1(I) procollagen and TGF-1 mRNA
levels induced by TGF-1 were decreased when both
TGF-3 and TGF-1 were added to dermal fibroblasts.
These studies led us to ask whether we could demon-
strate an antifibrotic effect of TGF-3 on extracellular
matrix production in renal cells. We also provided new
data of relevance to renal fibrosis on isoform actions and
interactions in terms of TGF- effects on matrix protein
synthesis and degradation.
METHODS
Materials
Recombinant human TGF-1, -2, and -3 were ob-
tained from R&D Systems, Inc. (Minneapolis, MN, USA)
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and reconstituted with sterile 4 mmol HCl containing
1mg/mL bovine serum albumin (BSA).
TGF- isoform-specific neutralization antibodies were
also obtained from R&D Systems, including anti-TGF-1
antibody (AF-101-NA); anti-TGF-2 antibody (AF-302-
NA); and anti-TGF-3 antibody (AF-243-NA). Pan-spe-
cific TGF- antibody, 1D11, which blocks isoforms
TGF-1, -2, and -3 was kindly provided by Genzyme
(Cambridge, MA, USA).
Unless otherwise indicated, materials, chemicals, or
culture media were purchased from Sigma Chemical Co.
(St. Louis, MO, USA).
Cell culture
Rat mesangial cells (RMC) were obtained from intact
glomeruli of four- to six-week-old Sprague-Dawley rats
and characterized according to published methods [1, 13,
14]. Cells were used between passages 6 and 9 and were
maintained in RPMI 1640 medium supplemented with
20% fetal bovine serum (FBS) (Hyclone Laboratory,
Logan, UT, USA), 100 U/mL penicillin, 100 g/mL strep-
tomycin, 0.1 U/mL insulin, 25 mmol N-2-hydroxyethylpi-
perazine-N-2-ethanesulfonic acid (HEPES) buffer at 37C
in a 5% CO2 incubator.
Rat tubular epithelial cells (NRK-52E) and renal fi-
broblasts (NRK-49F) were obtained from the American
Type Culture Collection (ATCC, Manassas, VA, USA)
and maintained in Dulbecco’s modified Eagle’s medium
(DMEM) supplemented with 5% FBS at 37C in a 5%
CO2 incubator.
Subconfluent mesangial cells and confluent renal fibro-
blast and tubular cells seeded on 6-well plates were made
quiescent by serum-free medium (containing 1 mg/mL
BSA) for 24 hours. For matrix protein measurements,
TGF- isoforms were added to cell cultures in doses
from 0.01 to 10 ng/mL and incubated for 24 hours (RMC,
NRK-49F) or 72 hours (NRK-52E).
In order to study the effects of combining TGF- iso-
forms, equal amounts of two isoforms were added to-
gether to cells in total doses from 0.01 to 10 ng/mL and
compared with the effect of the same dose of one isoform
alone. In addition, 1 ng/mL of one isoform was combined
with different dosages of other isoforms to see if different
ratios produced different effects. Finally, to simulate the
in vivo situation in which TGF-1 is present early, and
TGF-3 later, in tissue injury, renal fibroblasts were pre-
treated with TGF-1 (05 ng/mL) for 16 hours, and then
TGF-3 (05 ng/mL) was added for another 24 hours.
MTT assays
The number of living cells was determined by 3-[4,5-
dimethylthiazol]-2,5-diphenyltetrazolium bromide (MTT)
assay based on the activities of mitochondrial enzymes
in viable cells. At the termination of the experiment, all
media were replaced with serum-free medium containing
1 mg/mL MTT for 4 hours at 37C. After aspirating the
MTT solution, the purple formazan reaction product was
extracted from the cells with acidified isopropanol for
10 minutes by shaking, and then the optical density was
read on a ThermoMax microplate scanning spectropho-
tometer (Molecular Devices Corporation, Menlo Park,
CA, USA) at 562 nm with background subtraction at
650 nm.
Collagen assay
Collagen synthesis was measured by the incorporation
of [3H]-proline into collagen. Renal fibroblasts were cul-
tured and treated with TGF- isoforms as described
above. 1 Ci/mL L-[2,3,4,5-3H]-proline (Amersham Phar-
macia Biotech, Piscataway, NJ, USA) and 50 g/mL
ascorbic acid was added in the last 24 hours. Cells were
solubilized with 2 mL 0.5 N NaOH and collected with
medium into 4 mL 0.5 mol Tris-HCl, pH 7.4, containing
0.11 mol NaCl, 1 mmol unlabeled proline, and 1 mg/mL
albumin. Proteins were precipitated for 30 minutes with
8 mL ice-cold 20% trichloroacetic acid (TCA), and the
precipitates were collected after centrifugation for 15
minutes at 3000g. The supernatant was removed, and
the precipitate was dissolved and washed twice in 10 mL
of ice-cold 10% TCA. The resultant precipitate was dis-
solved in 0.5 mL 0.2 N NaOH. Duplicate 0.2 mL aliquots
were neutralized by 0.16 mL 0.15 mol HCl and 0.1 mL
1 mol HEPES/Tris buffer, pH 7.3, and added with 10 L
25 mmol CaCl2, 20 L 62.5 mmol N-ethylmaleimide and
20 L elution buffer (50 mmol Tris-HCl, pH 7.4, 5 mmol
CaCl2) or 20 L elution buffer containing purified colla-
genase (600 U/mL). After a 120 minute incubation pe-
riod at 37C with or without collagenase, the samples
were placed on ice and precipitated with 0.5 mL ice-cold
10% TCA plus 0.5% tannic acid. Acid-insoluble material
(noncollagen protein) was pelleted by centrifugation. The
supernatants were counted for  emission. The amount
of radioactivity solubilized by collagenase was subtracted
from the radioactivity of tubes without collagenase (non-
specific digest) as a measure of [3H]-proline incorporated
into collagen. All counts were corrected for cell number
[15–17].
Measurement of proteoglycan production by
metabolic labeling of cells
This assay was performed as previously described [18].
Briefly, rat mesangial cells were cultured and treated
with TGF- isoforms as described above. [35S]-sulfate
(200 Ci/mL) (NEN, Boston, MA, USA) was added in
the last 18 hours. At the end of experiments, superna-
tants were removed and analyzed by electrophoresis on
10% Tris-Glycine gels (Invitrogen, Carlsbad, CA, USA)
under reducing conditions. 14C protein molecular weight
marker was obtained from NEN. Gels were dried and
exposed to x-ray films for 72 to 96 hours. Autoradio-
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graphs were scanned on a Bio-Rad GS-700 imaging den-
sitometer (Bio-Rad Laboratories, Inc., Hercules, CA,
USA) to compare and quantitate the relative intensities
of proteoglycan bands.
Measurement of fibronectin, TGF-1, TGF-2, and
TGF-3 in culture supernatants
Fibronectin synthesis was measured with modified en-
zyme-linked immunosorbent assay (ELISA) according
to published methods [19]. For TGF- isoform ELISAs,
all supernatant samples were acid-activated. TGF-1 was
measured with a commercially available sandwich ELISA
kit (DuoSet, R&D Systems, Inc.) according to the man-
ufacturer’s instructions. TGF-2 sandwich ELISA sys-
tem was set up using MAB612 (R&D Systems, Inc.) as
capture antibody and BAF302 (R&D Systems, Inc.) as
detection antibody. Similarly, the TGF-3 ELISA used
MAB643 (R&D Systems, Inc.) as capture antibody and
BAF243 (R&D Systems, Inc.) as detection antibody.
Measurement of extracellular matrix degradation by
cultured renal fibroblast
Production of radioactive matrices. Renal fibroblasts
were seeded into 6-well plates at 5  104 cells/well. One
day later the culture medium was changed to DMEM
supplemented with 5% FBS, 50 g/mL ascorbic acid,
and 1 Ci/mL L-[2,3,4,5-3H]-proline and changed daily
thereafter. One week after seeding of the cells the cul-
tures were washed with phosphate-buffered saline (PBS).
Cells were lysed by the addition of 2 mL 25 mmol NH4OH
to each well for 30 minutes at 37C. The matrices left in
each well were washed carefully with PBS twice and kept
covered with sterile water at 4C until further use.
Degradation of the matrices by renal fibroblasts. Renal
fibroblasts were seeded onto labeled matrices at 5  104
cells/well. When cells grew to confluence, the medium
was carefully removed and the cells were washed with
serum-free DMEM medium and then incubated in 2 mL
DMEM with 5% FBS and different doses of TGF-
isoforms for 48 hours. At the end of the experiment,
supernatants were collected. To release undigested ra-
dioactivity from the matrix, 2 mL 2N NaOH were added
to each well and plates were incubated at 37C for 18
hours. Aliquots (50L) from both samples were counted
and results were expressed as the percentage of radioac-
tivity released into supernatants. Background values ob-
tained with medium placed on radiolabeled matrix in
the absence of cells were subtracted from these values
[20].
PAI-1 Western blot
Growth-arrested tubular epithelial cells were incu-
bated in serum-free medium with 0.1 mmol H2O2 and
different TGF- antibodies (AF-101-NA 1 g/mL; AF-
302-NA 1 g/mL; AF-243-NA 1 g/mL; and 1D11 10 g/
mL). The antibody dose was selected based on the neu-
tralization dose50 for each isoform and was sufficient to
block the corresponding isoform. Twenty-four hours later,
supernatants were collected for Western blot and cells
were used for MTT assays. Supernatants (40 L) were
separated by 10% Tris-glycine gel electrophoresis and
transferred to a 0.45 m nitrocellulose membrane (Milli-
pore, Bedford, MA, USA). Nonspecific binding was
blocked by 10% non-fat milk powder in Tris-buffered
saline (TBS) for 1 hour at room temperature, followed by
4C overnight incubation with primary antibody [stock
solution: 250 g/mL, rabbit-anti-rat plasminogen activa-
tor inhibitor type 1 (PAI-1) immunoglobulin G (IgG)
(American Diagnostica, Inc., Greenwich, CT, USA) di-
luted 1:200 in 5% BSA in TBS/0.1%Tween-20 with
0.02% NaN3]. The blot was washed three times for 10
minutes in TBS/0.1%Tween-20. The second antibody,
goat anti-rabbit horseradish peroxidase (stock solution:
400 g/mL; Santa Cruz Biotechnology, Inc., Santa Cruz,
CA, USA), was incubated at a dilution of 1:5000 for an
additional hour at room temperature, followed by three
washes as described above. Bound antibodies were de-
tected by developing the blot in enhanced chemilumines-
cence (ECL) Western blotting detection reagents
(Amersham Pharmacia Biotech) for 1 minute. Quantita-
tion of the bands on autoradiograms was performed us-
ing a Bio-Rad GS-700 imaging densitometer (Bio-Rad
Laboratories, Inc.).
RNA preparation and Northern hybridization
For Northern blots, renal fibroblasts and rat mesangial
cells were treated with TGF- isoforms for 8 hours and
tubular epithelial cells for 48 hours. Total RNA was
extracted by a guanidinium isothiocyanate method using
Trizol reagent according to the manufacturer’s instruc-
tions. For Northern analysis, RNA was denatured and
fractionated by electrophoresis through a 1.0% agarose
gel (20 g/lane) and transferred to a nylon membrane
(BrightStar Plus, Ambion, Inc., Austin, TX, USA).
Nucleic acids were immobilized by ultraviolet irradiation
(Stratagene, La Jolla, CA, USA). Membranes were pre-
hybridized with ULTRAhyb buffer (Ambion, Inc.)
and hybridized with DNA probes labeled with 32P-dATP
by random oligonucleotide priming (Strip-EZ DNA,
Ambion, Inc.). The blots were washed once for 10 min-
utes in 2 X SSC, 0.1% SDS at room temperature and
twice for 15 minutes in 0.1 X standard sodium citrate
(SSC), 0.1% sodium dodecyl sulfate (SDS) at 42C. DNA
probes used were rat GAPDH cDNA (kindly provided
by M.B. Sporn) [21]; rat procollagen 1 cDNA (kindly
provided by Dr. D. Rowe) [22]; fibronectin-EDA cDNA
(kindly provided by Dr. R.O. Hynes) [23]; TGF-1 and
-2 cDNA (kindly provided by Dr. H.L. Moses) [24, 25];
and TGF-3 (ATCC). Three blots per probe were per-
formed. Autoradiographic signals obtained with the
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Fig. 1. Effects of transforming growth factor
(TGF)-1, -2, and -3 on production of ex-
tracellular matrix (ECM) proteins by renal
fibroblasts. (A ) Production of fibronectin, (B )
collagen, and (C) mRNA expression. *P 
0.05 vs. control.
GAPDH cDNA probe served as control for equal load-
ing of the gel. Autoradiographs were scanned on a Bio-
Rad GS-700 imaging densitometer (Bio-Rad Labora-
tories, Inc.). Changes in mRNA levels were determined
by first correcting for the densitometric intensity of
GAPDH for each sample. For comparison, this ratio was
set at unity for normal control samples and other lanes
on the same gel were expressed as fold-increase over
this value.
Statistical analysis
Data are expressed as mean  SEM. Statistical analy-
sis of differences between the groups was performed by
analysis of variance (ANOVA) and subsequent Student-
Newman-Keuls or Dunnett testing for multiple compari-
sons. Comparisons with a P value0.05 were considered
significantly different. Triplicate wells were analyzed for
each experiment, and each experiment was performed
independently a minimum of three times.
RESULTS
TGF- isoforms -1, -2, and -3 stimulate
extracellular matrix protein production equally
Renal fibroblasts. Treatment of renal fibroblasts with
increasing concentrations of TGF- did not significantly
alter the number of living cells (data not shown). All
isoforms increased production of the matrix proteins fi-
bronectin (Fig. 1A) and collagen I (Fig. 1B) up to 200%
in a dose-dependent manner. The ED50 of this profibrotic
effect is approximately 0.05 ng/mL, and doses higher
than 1 ng/mL did not further increase matrix protein
production. These protein changes were consistent with
mRNA expression (Fig. 1C). No differences were found
among the three isoforms.
Tubular epithelial cells. TGF- isoforms did not alter
cell number (data not shown). Compared with fibroblasts,
which responded to TGF- isoforms within 24 hours,
the epithelial cell response was slow, showing no obvious
increase in fibronectin production until 72 hours of incu-
bation (data not shown). Measured at 72 hours, each iso-
form increased fibronectin production in a dose-dependent
manner (Fig. 2A). At the mRNA level, all TGF- isoforms
increased collagen I expression to about the same extent
as fibronectin expression (Fig. 2B).
Rat mesangial cells. Because the collagen and fibro-
nectin response of mesangial cells to TGF- was small
(data not shown), we measured changes in proteoglycan
synthesis. Proteoglycan production by mesangial cells
was significantly increased at the low dose (0.1 ng/mL)
of each TGF- isoform, reaching a maximum 3-fold in-
crease at 0.1 or 1.0 ng/mL (Fig. 3). Treatment of mesan-
gial cells with each isoform at 10 ng/mL caused a decrease
in proteoglycan production compared to that seen at
lower TGF- concentrations (Fig. 3).
TGF-b isoforms -b1, -b2, and -b3 similarly reduce extra-
cellular matrix protein degradation. Renal fibroblasts
cultured on renal fibroblast-produced radiolabeled ma-
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Fig. 2. Effects of transforming growth factor
(TGF)-1, -2, and -3 on production of ex-
tracellular matrix (ECM) proteins by tubular
epithelial cells. (A ) Production of fibronectin
and (B ) mRNA expression. *P  0.05 vs.
control.
Fig. 3. Effects of transforming growth factor
(TGF)-1, -2, and -3 on proteoglycan pro-
duction by renal mesangial cells. (A ) Effects
of TGF-1, (B ) TGF-2, and (C ) TGF-3.
Proteoglycan production by mesangial cells
was increased dose dependently up to 3-fold
the control level. *P  0.05 vs. control.
trix degraded the preexisting matrix proteins and re-
leased 3H into supernatant. Exogenously added TGF-
dose dependently inhibited extracellular matrix (ECM)
degradation. As shown in Figure 4, TGF-1 and -3
reduced matrix degradation approximately 75% at 10
ng/mL TGF-, while TGF-2 reduced matrix degrada-
tion less, reaching approximately 60% reduction at 10
ng/mL TGF-2.
Combination of TGF-b isoforms shows additivity in
their profibrotic action. We next asked whether we could
detect any antifibrotic effect of TGF-3 on renal cells
as has been reported in dermal scarring and in dermal
fibroblasts [11, 12]. We compared collagen production
by renal fibroblasts stimulated with TGF-1 or -3 alone
with collagen production stimulated with a mixture of
Fig. 4. Effects of transforming growth factor (TGF)-1, -2, and -3
on matrix degradation. * P  0.05 vs. control.
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Fig. 5. Additive effects of combinations of
transforming growth factor- (TGF-) iso-
forms on matrix protein production by renal
fibroblasts. (A) Collagen production in response
to 50%/50% TGF-1 and -3 (top left), 50%/
50% TGF-2 and -3 (top right), 0.05 ng/mL
TGF-1 combined with different amounts of
TGF-3 (bottom left) and 0.05 ng/mL TGF-3
combined with different amounts of TGF-1
(bottom Right). (B ) Fibronectin production
in response to 50%/50% TGF-1 and -3
(left) and 50%/50% TGF-2 and -3 (right).
(C ) TGF-1 (1 ng/mL) combined with differ-
ent doses of TGF-3 was added to fibroblasts
for 6 hours.
half -1 and half -3. Similarly, collagen production in
response to TGF-2 or TGF-3 added alone or in 1:1
combination was measured. The results, shown in the top
left and right panels of Figure 5A, indicate that the colla-
gen response of renal fibroblasts depends on the total
TGF- concentration added, and not on which isoform
is added. This result is seen over a wide range of total
TGF- concentrations from 0.01 to 10 ng/mL. Similarly,
if a constant amount of TGF-1 or TGF-3 (0.05 ng/mL)
is added with varying amounts of TGF-3 or TGF-1 (0
to 10 ng/mL), the collagen produced again is extremely
similar over a wide range of TGF- concentrations, as
shown in the bottom panels of Figure 5A. Figure 5B
shows the results of fibronectin production by renal fi-
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Fig. 6. Additive effects of combinations of transforming growth factor-
(TGF-) isoforms on matrix protein production by tubular cells.
TGF-1 (1 ng/mL) was combined with different doses of TGF-3 and
added to renal tubular epithelial cells. (A ) Fibronectin production dur-
ing 72-hour treatment. (B ) TGF- and matrix protein mRNA expres-
sion after 48-hour treatment.
broblasts in response to total TGF- concentrations from
0 to 10 ng/mL added as 1:1 TGF-1 and TGF-3 (Fig.
5B, left) or 1:1 TGF-2 and TGF-3 (Fig. 5B, right).
One can readily see, when comparing Figures 1A and
Figure 5B, that fibronectin production is very similar,
whether the total TGF- is composed of one or two
isoforms. Figure 5C shows the renal fibroblast mRNA
levels in response to constant -1 levels and increasing
-3 levels. Similar data are shown for fibronectin produc-
tion by renal epithelial cells in response to constant
TGF-1 levels and increasing TGF-3 levels (Fig. 6A).
Levels of mRNA are shown in Figure 6B. When 1 ng/mL
TGF-1 is added, fibronectin production and mRNA
levels increase (Figure 6A, second bar; Fig. 6B, second
lane). As shown in the third and fourth bars of Figure
6A and the third and fourth lanes of Figure 6B, when
0.1 or 1.0 ng/mL TGF-3 is added to this 1.0 ng/mL
TGF-1, both fibronectin protein and mRNA levels con-
tinue to increase as the total dose of TGF- increases.
Also, rat mesangial cells in response to addition of 1
ng/mL TGF-1, -2, or -3 show a marked increase in
proteoglycan production (Figure 7 A, B, and C, respec-
tively, 2 left bars). When TGF-3 is added to either -1
(Fig. 7A) or -2 (Fig. 7B), or when TGF-1 is added to
-3 (Fig. 7C), a further increase in proteoglycan produc-
tion is seen. Thus, for all three of the renal cell types
shown in Figures 5, 6, and 7, no evidence was found
suggesting that addition of TGF-3 in the presence of
another isoform leads to decreased matrix protein pro-
duction.
The final investigation of the possible antifibrotic ef-
fect of TGF-3 on renal cells involved addition of
TGF-1 to renal fibroblasts for 40 hours. During the last
24 hours, different doses of TGF-3 from 0 to 5 ng/mL
were added in an attempt to mimic the in vivo situation
of early expression of TGF-1 and later up-regulation
of TGF-3. When renal fibroblasts were pretreated with
TGF-1, collagen production was increased dose depen-
dently (Fig. 8). Later addition of TGF-3 resulted in
an obvious further dose-dependent increase in collagen
production when the preincubation concentration of
TGF-1 was low (0.05 ng/mL). No further increase and
no decrease were seen when TGF-1 (5 ng/mL) pretreat-
ment had already maximized collagen synthesis (Fig. 8).
Interactions among TGF-b isoforms in renal cells. We
next studied the unstimulated production of TGF- iso-
forms in the three cell types and the ability of one isoform
to increase the production of the other two. As a first
step we determined the specificity of the TGF- isoform
ELISAs. The results, shown in Table 1, indicate very
limited cross reactivity that was seen only at the highest
concentration. The unstimulated, endogenous produc-
tion of TGF-1, TGF-2, and TGF-3 in the three cell
types is shown in Table 2. In renal fibroblasts and tubular
epithelial cells, TGF-1 predominated, while rat mesan-
gial cells produced each isoform at a similar level. Tubu-
lar epithelial cells produced a large amount of TGF-1
in 72 hours compared with that produced by renal fibro-
blasts and mesangial cells in 24 hours (Table 2). TGF-2
was moderately expressed in tubular epithelial cells and
mesangial cells and was barely detectable in renal fibro-
blasts (Table 2). TGF-3 was not detected in renal fi-
broblasts and was moderately produced in both epithelial
cells and in mesangial cells (Table 2).
Production of TGF-1, TGF-2, or TGF-3 in re-
sponse to stimulation by the other two isoforms is shown
in rows 2-4 of Table 2, respectively. Corresponding
Northern blots are shown in Figure 9. TGF-2 and -3
stimulated TGF-1 production two-fold in renal fibro-
blasts. Tubular epithelial cells, with high endogenous
production of TGF-1, were less responsive to exoge-
nous TGF-. Addition of 1 ng/mL TGF-2 or -3 re-
sulted in a small increase in TGF-1 protein and no
detectable increase in mRNA. At the highest dose of
-2 or -3, TGF-1 production was increased 25% at
the protein level and considerably more at the mRNA
level. Mesangial cells showed two-fold, dose-dependent
increases in TGF-1 mRNA and protein in response to
TGF-2 and TGF-3 (Table 2 and Fig. 9).
Table 2 shows that TGF-2 production in fibroblasts
was stimulated almost three-fold by both TGF-1 and
-3, although -2 levels remained low. TGF-3 remained
undetectable in renal fibroblasts (Table 2). In addition,
stimulation of epithelial cells or mesangial cells with
TGF-1 or TGF-3 had little effect on production of
either TGF-2 or TGF-3. Similarly, stimulation of epi-
thelial cells or mesangial cells with TGF-3 or TGF-2
had no effect on production of TGF-2 or TGF-3, re-
spectively (Table 2).
We next investigated the ability of antibodies to TGF-1
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Fig. 7. Additive effects of combinations of
transforming growth factor- (TGF-) iso-
forms on matrix protein production by mesan-
gial cells. (A ) Mesangial cells were treated
with 1 ng/mL TGF-1 combined with different
doses of TGF-3 for 24 hours, (B ) TGF-2
(1 ng/mL) combined with different doses of
TGF-3, (C ) TGF-3 (1 ng/mL) combined
with different doses of TGF-1. *P  0.05 vs.
control.
Fig. 8. Effects of addition of transforming growth factor (TGF)-3
16 hours after addition of TGF-1 on collagen production by renal
fibroblasts. Open bars show a dose-dependent increase in collagen as
preincubation TGF-1 increases. Taking each set of bars, the data
show that at low TGF-1 concentration (0.05 ng/mL), later addition of
TGF-3 resulted in a dose-dependent increase in collagen synthesis.
As the preincubation concentration of TGF-1 increased, later addition
of TGF-3 resulted in smaller or no increase in collagen production.
or TGF-3 to reduce the actions of these isoforms to
increase fibronectin production. The specificities of the
TGF- isoform antibodies used in this study were tested
by R&D Systems, Inc. Cross-reactivity is less than 2%
for anti-TGF-1 and anti-TGF-2, and less than 10%
for anti-TGF-3. The results are shown in Figure 10.
The first two bars of each graph in figure 10 show that
addition of either anti-TGF-1 or anti-TGF-3 had no
effect on endogenous fibronectin production by either
renal fibroblasts (Fig. 10 A and C) or tubular epithelial
cells (Fig. 10 B and D). This suggests that baseline fibro-
nectin production in these cells is not dependent upon
exogenous TGF-1 or -3.
Comparing the first and third bars of each graph in
Figure 10, one can see the TGF-3- and TGF-1–induced
increases in fibronectin production. As expected, in-
creasing doses of the antibody corresponding to the iso-
form added block the increase in fibronectin production
Table 1. Cross-reactivity of TGF- isoform-specific enzyme-linked
immunosorbent assays (ELISAs)
Isoform Concentration Observed Cross-
added tested ng/mL value pg/mL reactivity %
A TGF-2 1.0 0 0
10.0 21.1 0.21
TGF-3 1.0 0 0
10.0 43.1 0.43
B 1.0 0 0TGF-1
10.0 32.1 0.32
TGF-3 1.0 0 0
10.0 12.7 0.13
C 1.0 0 0TGF-1
10.0 13.2 0.13
TGF-2 1.0 0 0
10.0 0 0
Row A shows TGF-1 ELISA values with TGF-2 and TGF-3; row B shows
TGF-2 ELISA values with TGF-1 and TGF-3; row C shows TGF-3 ELISA
values with TGF-1 and TGF-2.
(Fig. 10, third through fifth bars of each graph). The last
two bars of each graph show a different story. If fibro-
nectin production is increased by addition of TGF-1,
anti-TGF-3 cannot block this effect in fibroblasts. Since
TGF-3 was not detected in renal fibroblasts this is ex-
pected (Fig. 10A, right two bars). However, anti-TGF-3
also did not reduce fibronectin production by epithelial
cells (Fig. 10B, right two bars). This suggests that the
TGF-1–induced increase in fibronectin in epithelial
cells is not mediated at all by production of TGF-3. (It
also suggests that the limited reactivity between TGF-1
and this anti-3 antibody can be ignored in this experi-
ment.) In contrast, if fibronectin production is induced
with TGF-3, addition of anti-TGF-1 blocks the ob-
served increase in fibronectin production 77% and 86%,
respectively, in fibroblasts and epithelial cells (Fig. 10 C
and D, right two bars). This strongly suggests that a
large component of the action of TGF-3 to increase
fibronectin synthesis is mediated by production of TGF-1.
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Table 2. Effects of TGF- isoforms -1, -2 and -3 on production of TGF- isoforms by renal cells
A TGF-1 (pg/mL) produced in response to TGF-2 or TGF-3
TGF-2 TGF-3
Dose
ng/mL NRK-49F NRK-52E RMC NRK-49F NRK-52E RMC
0 1303.7 130737 54.83.1 1573.7 138729 54.85.4
0.1 1932.0a 130243 93.09.5a 2302.2a 134327 99.24.6a
1 2454.4a 152012a 1065.5a 26915a 152617a 1142.0a
10 24810a 172950a 1182.5a 2706.4a 173368a 1295.4a
B TGF-2 (pg/mL) produced in response to TGF-1 or TGF-3
TGF-1 TGF-3
Dose
ng/mL NRK-49F NRK-52E RMC NRK-49F NRK-52E RMC
0 24.09.5 1703.7 1134.4 22.43.3 1797.3 1134.4
0.1 47.15.4 18817 1198.3 24.21.6 1776.1 1158.3
1 62.50.6a 18812 1127.7 64.36.1a 2097.0a 1132.5
10 64.46.3a 2186.0a 1164.6 63.07.2a 2422.3a 1103.0
C TGF-3 (pg/mL) produced in response to TGF-1 or TGF-2
TGF-1 TGF-2
Dose
ng/mL NRK-49F NRK-52E RMC NRK-49F NRK-52E RMC
0 0 1405.2 17423 0 12610 17423
0.1 0 1365.3 2026.2 0 1334.7 18912
1 0 12210 19515 0 1115.3 18615
10 0 1394.4 1908.4 0 11811 19016
aP  0.05 vs. control
Fig. 9. Effects of transforming growth factor- (TGF)- isoforms -1,
-2, and -3 on isoform mRNA expression. (A ) Renal fibroblasts, (B )
tubular epithelial cells, (C ) mesangial cells.
Blockade of TGF-b isoforms in “fibrotic” tubular epi-
thelial cells. Finally, we attempted to mimic an in vivo
fibrotic situation using oxidative stress and isoform-spe-
cific antibodies to determine the effectiveness of block-
ade of TGF- isoforms on production of the marker of
fibrosis, PAI-1. As seen in Figure 11 A and B, the addi-
tion of hydrogen peroxide (0.1 mmol) increased TGF-1
and TGF-2 production. The 24-hour treatment period
yielded TGF-3 levels that were too low to be detected
by ELISA (Fig. 11). Based on absolute levels of TGF-
produced by peroxide stimulation, TGF-1 appears to
be the main isoform involved. The first two bars from the
left in Figure 11C show the very large, 22-fold increase in
PAI-1 protein in response to peroxide. Large concentra-
tions of isoform-specific antibodies were then added to
peroxide-treated cells. As seen in the fourth to sixth bars
of Figure 11C, all three isoform-specific antibodies yielded
reductions in PAI-1 production. The reduction reached
significance only for anti-TGF-1. The last bar of Figure
11C shows that a combination of all three isoform-specific
antibodies was more effective than any isoform-specific
antibody alone. The pan-specific mouse monoclonal anti-
body 1D11, shown in the third bar of Figure 11C, was most
effective at reducing the peroxide-induced increases in
PAI-1 production. If one uses the difference in PAI-1
production between control and peroxide-stimulated
cells as 100%, PAI-1 production was reduced 29% by
anti-1, 13% by anti-2, 16% by anti-3, 36% by a com-
bination of the three isoform-specific antibodies, and
44% by the pan-specific antibody, 1D11. These results
indicate that blockade of all three isoforms is most effec-
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Fig. 10. Effects of anti-transforming growth
factor- (TGF)-1 and anti-TGF-3 on fibro-
nectin production. (A and C ) Renal fibro-
blasts. (B and D) Epithelial cells. TGF-3 anti-
body dose dependently neutralized TGF-3
effect. Blockade of TGF-3 had no effect on
TGF-1’s effect (A, B). TGF-1 antibody
dose dependently neutralized TGF-1’s effect.
Blockade of TGF-1 reduced TGF-3’s effect
on fibronectin production by 76.7% in fibro-
blasts (C) and 85.6% in epithelial cells (D).
Fig. 11. Effects of transforming growth factor- (TGF-) blockade
on plasminogen activator inhibitor type 1 (PAI-1) production after
treatment of epithelial cells with H2O2. Stimulation with H2O2 caused
marked increases in (A ) TGF-1, (B ) TGF-2, and (C ) PAI-1 produc-
tion. Blockade of all TGF-s significantly reduced PAI-1 production
(C). *P  0.05 vs. H2O2. TGF-3 levels were too low to be measured
(data not shown).
tive in reducing peroxide-induced increases in PAI-1
production. Interestingly, the data also show that 56%
of the peroxide-induced up-regulation of PAI-1 is TGF-
–independent.
DISCUSSION
The results of this study clearly show that addition of
TGF-1, -2, or -3 to three types of renal cells produced
very similar effects on matrix protein metabolism. Al-
though there were differences in the magnitude of re-
sponse among the cell types, all TGF- isoforms dose
dependently increased matrix protein synthesis and re-
duced matrix degradation (Figs. 1–4).
The three mammalian TGF- isoforms are encoded
by distinct genes. They are synthesized as large prepro-
proteins, of which the biologically active TGF- isoforms
reside in the C-terminus. Although their N-terminal pre-
cursor sequences are dissimilar, the C-terminal 112
amino acids of the mature TGF- peptides exhibit 60%
to 80% conservation and 100% conservation of the nine
cysteine residues [26]. In most biological aspects they
are interchangeable. The clear difference among them
is tissue-specific and developmentally regulated expres-
sion. TGF-1 is expressed in endothelial, hematopoietic,
and connective tissue cells; TGF-2 in epithelial and
neuronal cells; and TGF-3 primarily in mesenchymal
cells. In normal kidney, TGF-1 is expressed in glomeruli
and tubules, predominantly in distal tubules. TGF-1
mRNA has been found in tubular epithelial cells, mesan-
gial cells, glomerular epithelial cells, as well as interstitial
fibroblast like cells [27]; TGF-2 mRNA and protein
was found in glomeruli and tubular cells. Potassium
depletion or water deprivation induced TGF-2 in renal
arteries and the juxtaglomerular apparatus [28–30];
TGF-3 expression was located at tubular cells and to
a lesser extent in glomeruli [29, 30]. During development,
TGF-1 and -3 are expressed early in structures under-
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going morphogenesis, and TGF-2 is expressed later in
mature and differentiating epithelium [31, 32]. In a tissue
where all three isoforms are expressed it is not clear
whether they act synergistically.
At the level of signal transduction, TGF-2 is different
from the other two isoforms. TGF-1 and -3 directly
combine with the type II TGF- receptor (TRII). The
complex activates the type I TGF- receptor (TRI) and
signaling proceeds. In contrast, TGF-2 needs the type
III TGF- receptor (TRIII, betaglycan) in order to
combine with TRII [33]. Thus, it is possible that some
cells respond differently to TGF-2, as has been shown
in some studies [34, 35]. However, most studies have
shown similar profibrogenic effects of TGF-2, probably
because TRIII is widely expressed [9, 10, 36]. In the
present study, addition of exogenous TGF-2 to renal
cells produced increases in matrix production that were
interchangeable with those seen with addition of TGF-1.
There has been a great deal of controversy over the
reported anti-fibrotic effect of TGF-3. A number of in
vitro studies have failed to show antifibrotic effects of
TGF-3 [9, 10, 36, 37]. On the other hand, Murata et al
[12] observed that addition of TGF-3 to dermal fibro-
blasts increased collagen production when added alone,
but when both TGF-1 and TGF-3 were added to-
gether, 1(I) procollagen and TGF-1 mRNA levels de-
creased. These data may result from the well-known
phenomenon that low levels of TGF- increase matrix
protein production while very high doses decrease matrix
production in some cell types. Thus, it was not surprising
that when 1 or 5 ng/mL TGF-3 was added to 1 ng/mL
TGF-1, mRNA expression decreased. In the present
study we first determined dose response curves for all
isoforms. Mesangial cell proteoglycan production showed
decreases at high doses, while renal fibroblast and tubu-
lar epithelial cell matrix protein synthesis leveled off at
high doses. Because of the sensitivity and reproducibility
of the 3H-proline incorporation assay, we used collagen
production as a read-out for isoform effects in most of
the studies. The data indicate that all three isoforms
increase matrix protein production and they are equipo-
tent. Whether we added isoforms together simultane-
ously, whether different ratios of isoforms were used, or
whether TGF-3 was added at a later time than TGF-1,
we could find no anti-fibrotic effects of TGF-3 in these
cells.
We also investigated the possibility that TGF- iso-
forms differentially reduce matrix protein degradation
that could result in different levels of pathologic matrix
accumulation. While increased PAI-1 production is gen-
erally thought to result in decreased matrix degradation
via decreased plasmin generation, the only direct evi-
dence has been provided in studies by Baricos et al [38].
PAI-1 was shown to mediate human mesangial cell deg-
radation of radiolabeled matrigel and TGF-1 was later
shown to mediate the decreased degradation seen with
increased PAI-1 production [39]. We found TGF-2 and
-3 also increased PAI-1 expression on these renal cells
(data not shown). The data presented here show that
renal fibroblasts cultured on their own matrix degrade
the pre-existing matrix proteins as they produce new
ones and that all TGF- isoforms reduce this matrix
degradation similarly. The question of whether this de-
crease is entirely mediated by PAI-1 is, as yet, unknown.
While the in vitro data presented here suggest that
TGF-3 has no anti-fibrotic actions, it is possible that
the in vivo and in vitro situations differ. The first study
suggesting TGF-3 had anti-fibrotic effects came from
a rat model of wound repair. Shah et al [11] reported
that exogenous addition of the TGF-3 to rat dermal
wounds reduced monocyte/macrophage infiltration, as
well as fibronectin, collagen I, and collagen III deposition
in the early stages of wound healing. The architecture of
the neodermis was improved and scarring was reduced.
However, the rat incisional model has been questioned
by other researchers because rat wounds usually heal
without an obvious scar [40]. In addition, in Shah’s study,
TGF- isoforms and antibodies were injected into differ-
ent wounds on the same rat, introducing the question of
whether systemic effects might explain their results. In
fact, when Tyrone et al [41] did similar experiments on
rabbits they found the opposite results. Exogenous TGF-3
significantly increased the wound-breaking strength and
collagen deposition.
Interpretation of our in vitro studies may also be lim-
ited because of the multiple roles of TGF- in vivo.
While TGF- is chemotactic for monocytes and neutro-
phils, which would enhance inflammation, TGF- may
also suppress activated inflammatory cells, thereby de-
creasing inflammation [42, 43]. Only empirical in vivo
data on TGF- isoforms will truly shed light on whether
inflammation is an important factor in many fibrotic dis-
eases. For example, a study on nephrotoxic nephritis
with TGF-3 infusion showed profound reduction of
macrophage infiltration, but no decrease in glomerular
matrix accumulation [30].
Perhaps the most interesting and clinically relevant
finding in this study is that while TGF-1 had a small
and inconsistent action on TGF-2 and -3 synthesis,
TGF-2 and -3 up-regulated TGF-1 expression in all
three cell types. This led us to hypothesize that the pro-
fibrotic actions of TGF-2 and TGF-3 may be mediated
by TGF-1. Use of isoform-specific antibody to TGF-3
revealed that nearly 80% of the profibrotic effect of
TGF-3 in tubular epithelial cells and renal fibroblasts
was dependent on induction of TGF-1 synthesis by
TGF-3. In contrast, the profibrotic actions of TGF-1
were not mediated by TGF-3. This is consistent with
Murata’s work on dermal fibroblasts, in which more than
50% of the stimulatory effect of TGF-3 on1(I) procol-
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lagen mRNA expression could be inhibited by TGF-1
anti-sense oligonucleotide [12]. When one combines
these findings with the fact that TGF-1 production by
these renal cells is quantitatively greater than production
of TGF-2 and TGF-3, it appears likely that TGF-1
is the major mediator of fibrogenesis in renal cells.
The interactive relationship between isoforms was fur-
ther demonstrated in an in vitro system. Oxidative stress
causes renal injury and promotes renal fibrosis [44, 45].
In this study, exposure of tubular epithelial cells to hy-
drogen peroxide produced dramatic increases in PAI-1
protein production (Fig. 11C). This was accompanied by
up-regulation of TGF-1 and -2 (Fig. 11 A and B).
Blockade of TGF-1, TGF-2, or TGF-3 reduced PAI-1
by 29%, 13%, and 16%, respectively. A further reduction
to 44% was achieved by blocking all three isoforms to-
gether, suggesting that pan-specific blockade of all TGF-
isoforms may be the best strategy for therapeutic reduc-
tion of fibrosis. Consistent with this idea is the fact that
expression of all three TGF- isoforms is increased in
most human renal fibrotic diseases [46, 47]. Interestingly,
the PAI-1 increase in response to peroxide treatment
could only be blocked by 44%, indicating that TGF-
–independent pathways are responsible for part of this
increase.
CONCLUSION
The study presented here demonstrates a clear profi-
brotic effect of all three TGF- isoforms. It suggests that
increases in any of the TGF isoforms can contribute to
pathologic matrix accumulation in renal fibrosis. Although
TGF-1 may be the main mediator, blockade of all iso-
forms together may yield the best therapeutic effect.
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